• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Annovis Bio Inc.

    4/30/26 5:02:41 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANVS alert in real time by email
    DEFA14A 1 tm261540d2_defa14a.htm DEFA14A

    GRAPHIC

    ANNOVIS BIO, INC. Mr AB Sample Sample Street Sample Town Sampleshire, XXX XXX Important Notice Regarding the Internet Availability of Proxy Materials for the Annual Meeting of Stockholders to be held virtually on June 17, 2026 at 10:00 a.m. ET This communication is not a form of voting and presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Proxy Statement and Annual Report are available at https://web.viewproxy.com/annovisbio/2026 If you want to receive a paper or e-mail copy of these documents, you must request one by following the instructions below on or before June 8, 2026 to facilitate timely delivery. There is no charge to you for requesting a copy. Important information regarding the Internet availability of the Company’s proxy materials, instructions for accessing your proxy materials and voting online, and instructions for requesting paper or e-mail copies of your proxy materials are outlined in this Notice. You must use the 11-digit Virtual Control Number located in the box to attend the Annual Meeting virtually, to vote via Internet, or to request proxy materials. CONTROL NUMBER STOCKHOLDERS ARE CORDIALLY INVITED TO ATTEND THE ANNUAL MEETING. To the Stockholders of Annovis Bio, Inc.: The 2026 Annual Meeting of Stockholders of Annovis Bio, Inc. will be held virtually on Wednesday, June 17, 2026 at 10:00 a.m. ET. In order to attend the meeting, you must register at https://web.viewproxy.com/annovisbio/2026 by 11:59 PM EDT on June 16, 2026. You will receive a meeting invitation by e-mail with your unique join link along with a password prior to the meeting date. Stockholders will be able to listen, vote and submit questions during the virtual meeting. Further instructions on how to attend and vote at the Annual Meeting of Stockholders are contained in the Proxy Statement in the section titled “Questions and Answers About the Proxy Materials and Our Annual Meeting - What do I need to do to attend the Annual Meeting virtually?”. The Board of Directors recommends a vote “FOR” all the nominees listed in Proposal 1, “FOR” Proposals 2, 3 and 4, and “2-YEARS” on Proposal 5. 1. ELECTION OF DIRECTORS: (1) Michael Hoffman (2) Maria Maccecchini (3) Claudine Bruck (4) Reid McCarthy (5) Mark White 2. To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 3. To approve an amendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan (the “Option Plan”) 4. To approve an advisory (non-binding) proposal on our executive compensation 5. To approve an advisory (non-binding) proposal regarding the frequency with which stockholders should vote on our executive compensation Note: To transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.

    GRAPHIC

    Internet: Go to https://web.viewproxy.com/annovisbio/2026 Have the 11-digit Virtual Control Number available when you access the website and follow the instructions. Telephone: Call 1-877-777-2857 Toll Free E-Mail: By e-mail at: requests@viewproxy.com * If requesting material by e-mail, please send a blank e-mail with the company name and your 11-digit Virtual Control Number in the subject line. No other requests, instructions, or other inquiries should be included within this email request. The Securities and Exchange Commission rules permit us to make our proxy materials available to our stockholders via the Internet. Material for this Annual Meeting and future meetings may be requested by one of the following methods: Via Internet prior to the Annual Meeting: Go to https://www.web.viewproxy.com/annovisbio/2026 Have your 11-digit Virtual Control Number available and follow the prompts. • Your electronic vote prior to the Annual Meeting authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned a proxy card. Via Internet during the Annual Meeting: Go to https://www.web.viewproxy.com/annovisbio/2026 You must register in advance to attend the Annual Meeting and vote your shares. Have your 11-digit Virtual Control Number available during the Annual Meeting in order to vote. Via Telephone: Call 1-866-804-9616 Use any touch-tone telephone to vote your proxy. Have your 11-digit Control Number available. Follow the voting instructions to vote your shares. Via Mail: Follow the instructions above to request materials for this Annual Meeting which includes a proxy card. Follow the instructions on the proxy card for voting by mail. VOTING METHODS ANNOVIS BIO, INC. CONTROL NUMBER

    Get the next $ANVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANVS

    DatePrice TargetRatingAnalyst
    7/8/2026$8.00Buy
    Roth Capital
    2/10/2025Buy → Hold
    D. Boral Capital
    10/25/2024$25.00Hold → Buy
    Maxim Group
    12/29/2023$36.00Buy
    Canaccord Genuity
    7/7/2021$45.00 → $150.00Buy
    Maxim Group
    More analyst ratings

    $ANVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

    Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for two NDA submissions following each readout MALVERN, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced full enrollment of its pivotal Phase 3 trial (NCT06709014) evaluating buntanetap in patients with early AD. The trial enrolled 85

    7/7/26 7:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

    MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer. Dr. Fang, who joined Annovis in 2021 and most recently served as Senior Vice President, Research and Development, will lead scientific strategy and research operations across the Company's AD and PD programs, including translational science, clinical development, biomarker strategy, and regulatory interaction

    7/1/26 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Bio Regains NYSE Listing Compliance

    MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today that it has regained compliance with the New York Stock Exchange (NYSE) continued listing standards. On March 26, 2025, the NYSE notified Annovis of its non-compliance with Section 802.01B of the NYSE Listed Company Manual, as the Company's average global market capitalization had fallen below $50 million over a consecutive 30-trading-day period while its stockholders' equi

    5/26/26 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    SEC Filings

    View All

    Annovis Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Annovis Bio, Inc. (0001477845) (Filer)

    7/9/26 9:06:20 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Annovis Bio Inc.

    8-K - Annovis Bio, Inc. (0001477845) (Filer)

    6/17/26 4:50:41 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Annovis Bio, Inc. (0001477845) (Filer)

    5/20/26 4:15:21 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Annovis Bio with a new price target

    Roth Capital initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $8.00

    7/8/26 9:18:09 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Bio downgraded by D. Boral Capital

    D. Boral Capital downgraded Annovis Bio from Buy to Hold

    2/10/25 8:18:59 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Bio upgraded by Maxim Group with a new price target

    Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00

    10/25/24 7:56:01 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hoffman Michael B bought $142,779 worth of shares (76,344 units at $1.87), increasing direct ownership by 2% to 3,364,883 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    5/21/26 8:11:23 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Hoffman Michael B

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    4/3/26 5:06:28 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoffman Michael B bought $193,794 worth of shares (45,000 units at $4.31), increasing direct ownership by 2% to 2,574,739 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    12/8/25 8:05:14 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hoffman Michael B bought $142,779 worth of shares (76,344 units at $1.87), increasing direct ownership by 2% to 3,364,883 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    5/21/26 8:11:23 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoffman Michael B bought $193,794 worth of shares (45,000 units at $4.31), increasing direct ownership by 2% to 2,574,739 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    12/8/25 8:05:14 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Hoffman Michael B bought $159,886 worth of shares (39,200 units at $4.08), increasing direct ownership by 2% to 2,529,739 units (SEC Form 4)

    4/A - Annovis Bio, Inc. (0001477845) (Issuer)

    11/25/25 6:59:54 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Financials

    Live finance-specific insights

    View All

    Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease

    Data Shows Statistically Significant Improvements in Speed and Motor Function in PD PatientsAnnovis Bio to Request Meeting with FDA on Next Steps in Clinical DevelopmentInvestor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ETBerwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor funct

    10/5/21 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Leadership Updates

    Live Leadership Updates

    View All

    Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

    MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer. Dr. Fang, who joined Annovis in 2021 and most recently served as Senior Vice President, Research and Development, will lead scientific strategy and research operations across the Company's AD and PD programs, including translational science, clinical development, biomarker strategy, and regulatory interaction

    7/1/26 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

    MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results. "The past quarter delivered breakthrough progress on every front," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "Our pivotal Phase 3 Alzheimer's study has achieved full activation across all clinical sites, with enrollment momentum advancing every day. We have fortified our intellectual property position by transferring al

    11/12/25 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Appoints Mark Guerin as Chief Financial Officer

    MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development. Mr. Guerin has extensive experience and a successful track record in managing financial operations within biopharma companies. In 2013, he joined Onconova Therapeutics, now known as Traws Phar

    9/25/25 7:30:00 AM ET
    $ANVS
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Annovis Bio Inc. (Amendment)

    SC 13G/A - Annovis Bio, Inc. (0001477845) (Subject)

    11/28/23 4:05:14 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Annovis Bio Inc.

    SC 13G - Annovis Bio, Inc. (0001477845) (Subject)

    11/8/23 7:02:36 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care